Precigen Shares Drop 3.4% as FDA Decision on INO‑3107 Looms
Precigen shares dip 3.4% as the FDA’s upcoming decision on competitor INO‑3107 threatens its sole RRP therapy—investors weigh the market’s reaction and potential shift in competitive advantage.
3 minutes to read
